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ABSTRACT 
Background: Mass distributions of azithromycin for trachoma have been associated with 
secondary benefits, including reductions in child mortality.  
Methods: In the PRET cluster-randomized trial for trachoma in Niger, 24 communities were 
randomized to annual treatment of everyone and 24 communities were randomized to biannual 
treatment of children under 12 for 3 years (clinicaltrials.gov, NCT00792922). Treatment was a 
single dose of directly observed oral azithromycin (20mg/kg up to 1gm in adults). Vital status 
was assessed during annual census and monitoring visits. In this pre-specified secondary 
analysis, we compared the mortality rate among children 6 months to less than 5 years of age by 
treatment arm using negative binomial regression.  
Results: Among children 6 months to less than 5 years of age, 404 deaths occurred during the 
study period. The mortality rate was 35.6 deaths per 1000 person-years (231 deaths, 95% CI 
30.9-40.9) in the annual arm and 29.0 deaths per 1000 person-years (173 deaths, 95% CI 24.8 to 
33.8) in the biannual arm. The mortality rate ratio comparing children in the biannual arm to the 
annual arm was 0.81 (95% CI 0.66 to 1.00, P = 0.07; primary outcome). The mortality rate ratio 
comparing children who died from infectious causes in the biannual arm to the annual arm was 
0.73 (95% CI 0.57 to 0.94, P=0.02). No adverse events were reported. 
Conclusions: This secondary analysis of a cluster-randomized trial found a non-significant 19% 
decrease in mortality among children 6 months to less than 5 years of age who received biannual 
azithromycin compared with children who received annual azithromycin. This study was 
conducted in a high mortality, trachoma-endemic area, thus results may be specific to this 
environment only. In addition, the trial was neither designed nor powered to detect a mortality 
effect, and we cannot rule out the possibility that mortality differences resulted from bias. 
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INTRODUCTION 
Mass distribution of oral azithromycin for trachoma has been associated with both intended and 
unintended effects. Mass azithromycin has been shown to reduce the prevalence of the 
Chlamydia trachomatis infection that causes the disease.(1) Secondary benefits include 
reductions in respiratory and gastrointestinal infections as well as malaria, all of which are 
among the leading contributors to childhood mortality in areas affected by trachoma.(2-5) On the 
other hand, the mass distribution of antibiotics is not without potential risks. Mass distribution 
could theoretically increase resistance of chlamydia to azithromycin, although previous studies 
have found no evidence of this even after multiple rounds of antibiotics.(6-8) Mass azithromycin 
selects for macrolide-resistant strains of other organisms, such as Streptococcus pneumoniae, at 
least until distributions are discontinued.(9-11) 
Mass azithromycin distributions for trachoma may reduce childhood mortality.(12, 13) Any 
potential mortality benefit of mass azithromycin would likely occur by reducing the burden and 
severity of common childhood infections. Studies finding reductions in infectious disease burden 
within the first 3 months after azithromycin have also found little to no effect 3 to 6 months after 
administration.(2, 3) Thus, the annual schedule of mass azithromycin normally distributed for 
trachoma may not be sufficient for widespread mortality benefits. Multiple treatments per year 
may increase the time a child is exposed to an antimicrobial while also increasing the chances of 
coverage during seasonal peaks of different infectious diseases.(14) Here, our objective was to 
compare the community-level effects of annual versus biannual mass azithromycin on all-cause 
mortality in children 6 months to less than 5 years of age in a pre-specified secondary analysis of 
the PRET cluster-randomized trial for trachoma conducted in Niger. A cluster-randomized trial 
allows us to assess mortality effects at the level of the intervention, the community. 
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MATERIALS AND METHODS 
Study setting and participants.  
This study was part of the Partnership for the Rapid Elimination of Trachoma (PRET) cluster-
randomized trials in The Gambia, Niger, and Tanzania.(15)  The Niger trial enrolled participants 
from 48 grappes (communities) in 6 Centres de Santé Intégrées (CSI) within the Matameye 
District in the Zinder Region.  Detailed eligibility criteria for participation in the Niger trial have 
been previously reported.(16, 17) Briefly, communities with populations between 250 and 600 
per the most recent government census were eligible for participation in the trial. Communities 
with less than 10% prevalence of active trachoma among children younger than 72 months were 
excluded.   
Institutional Review Board (IRB) approval was obtained from the University of California, San 
Francisco Committee for Human Research and the Comité d’Ethique du Niger (the Ethical 
Committee of Niger). Both IRBs approved verbal consent, which was obtained from each local 
community chief before randomization and from each individual or guardian prior to data 
collection. The study was implemented in accordance with the Declaration of Helsinki. The Data 
and Safety Monitoring Committee (DSMC) met annually to review study progress and reported 
adverse events. PRET was registered at clinicaltrials.gov (NCT00792922). 
Randomization and masking. 
This study employed a 2x2 factorial design to examine both treatment frequency and treatment 
coverage.  Communities were randomized into 4 arms of 12 communities each: 1) annual 
azithromycin treatment at standard (80%) coverage, 2) annual treatment at enhanced (90%) 
coverage, 3) biannual treatment at standard (80%) coverage, and 4) biannual treatment at 
enhanced (90%) coverage. Standard coverage (80%) was chosen as a target for the original trial 
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in line with the World Health Organization’s recommendation for coverage in trachoma control 
programs.(18) In addition, the randomization was stratified and blocked based on trachoma 
prevalence in children, as has been described previously.(16, 17) This report compares the 2 
annual treatment arms to the 2 biannual treatment arms. The randomization allocation was 
generated at the community level by Travis C. Porco using R (R Foundation for Statistical 
Computing, Vienna, Austria; www.r-project.org) and the sequence was implemented by study 
staff at UCSF and in Niger. Study personnel conducting the annual census were not informed of 
treatment allocation and were different from those conducting treatment visits. 
Interventions and procedures. 
The 24 communities randomized to annual mass distribution of oral azithromycin received 3 
rounds of treatment over 3 years in all persons 6 months of age or older. The 24 communities 
randomized to biannual distribution of oral azithromycin received 6 rounds of treatment in 
children 6 months to 12 years of age during the 3-year study period. The original trial targeted 
ages 6 months to 12 years in the biannual arm to ensure those treated twice per year formed a 
core group.(19) In both arms, treatment was a single dose of directly observed oral azithromycin 
(20mg/kg up to a maximum dose of 1gm in adults). Children under 6 months of age and those 
allergic to macrolides were given topical tetracycline ointment (1%) to be applied to both eyes 
twice a day for 6 weeks.  In the annual treatment arm, pregnant women were also offered topical 
tetracycline.  
An annual census was conducted over the 3-year period to enumerate the study population. 
Treatment was administered based on census data after the completion of data collection. 
Trachoma was monitored during separate biannual study visits in both arms. Community 
residents were advised to alert village health workers within 2 weeks following mass treatment if 
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they and/or their children experienced a serious adverse event, defined as diarrhea, nausea and 
vomiting for more than 2 days, hospitalization for any cause, or death. Residents were referred to 
the nearest health care center as needed.  
Outcomes. 
The pre-specified outcomes for the present study were: 1) community-level all-cause mortality 
rate among children 6 months to less than 5 years of age by treatment arm over the 3-year study 
period; and 2) community-level infectious disease mortality rate among children 6 months to less 
than 5 years of age by treatment arm over the 3-year study period. This age group was chosen as 
it is at the highest risk for mortality. Vital status was recorded at each annual census, treatment 
visit, and biannual trachoma monitoring visit by data collectors masked to treatment arm. 
Absences of individuals recorded during a previous census were noted along with the reason for 
the absence, if possible to determine. Treatment coverage was determined based on the study 
population enumerated during the census directly preceding the treatment period.  
For deaths reported during data collection, verbal autopsy was obtained using the 2007 World 
Health Organization verbal autopsy instrument. Causes of deaths were ascribed using a validated 
hierarchical expert algorithm.(20) This method utilizes a symptoms-based algorithm developed 
by experts in global child mortality to ascribe cause of death and, in the case of multiple causes, 
allocates a single cause of death using a hierarchy of causes. For this study, attributed causes of 
death were defined as infectious or non-infectious. Attributed infectious causes of death included 
all primary causes of death as determined by the algorithm except injury, malnutrition, and 
unspecified. 
Children included on the census who were either younger than 6 months or were 5 years to less 
than 12 years of age were included in exploratory analyses, as were adults 15 years of age and 
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older. Children 12 years to less than 15 years of age were not included in analyses, as this group 
received treatment in the biannual arm only during part of the study period. An additional 
analysis combined children 6 months to 12 years of age. 
Statistical analysis. 
The sample size was calculated with respect to the overall primary outcome of the main trial 
(prevalence of C. trachomatis infection in children), accounting for clustering by community and 
the factorial design. Assuming a standard deviation in the community-level prevalence of 5%, 
we estimated that 48 communities (24 communities per arm) would provide greater than 80% 
power to detect an absolute difference of 6% in the prevalence of infection among children.  
Note that this would provide 80% power to detect a 34% difference in the mortality rate among 
children 6 months to less than 5 years of age, assuming a mortality rate of 34.3 deaths per 1000 
person-years in the annual arm and a standard deviation of 0.014. 
The pre-specified analysis for the present study was negative binomial regression to compare 
mortality rates among children 6 months to less than 5 years of age at the community level 
between the biannual and annual treatment arms. The models included count of deaths per 
community over the 3-year study period as the outcome, log person-time per community as an 
offset, and treatment arm as a covariate. Person-time at risk was estimated as the inter-census 
interval in years multiplied by the number of individuals at the prior census, minus half of the 
number of the individuals who died, moved, or were lost to follow-up. Exploratory analyses 
were conducted using similar models to compare mortality rate by arm across all age groups as 
well as the combined group with children 6 months to 12 years of age. Loss to follow-up, 
including those who moved, was compared between arms for each age group. 
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To assess whether attributed cause of death differed between the 2 arms, we computed the chi-
squared statistic. We used negative binomial regression to compare infectious disease mortality 
rate among children 6 months to less than 5 years by arm, as pre-specified in the analysis plan 
and described above.  Specifically, we compared mortality rates by arm among children whose 
ascribed causes of deaths were infectious.  
P-values for all analyses were determined by Monte Carlo permutation (n=16,384) at the level of 
the randomization unit (community), accounting for the stratified design. The dispersion 
parameter used in negative binomial regression and the permutation P-values account for 
clustering at the level of the randomization unit, the community. 
RESULTS 
In May 2010, 48 communities in Niger were randomized to receive either annual or biannual 
mass azithromycin and were monitored until September 2013 (Figure 1, online only). At 
baseline, the 24 annually treated communities had a mean of 114 children per community (95% 
CI 88 to 156) and the 24 biannually treated communities had a mean of 107 children per 
community (95% CI 89 to 127, Table 1). Baseline characteristics of eligible children 6 months to 
less than 5 years of age were comparable between treatment arms (Table 1). All study 
communities were treated per protocol and no communities were lost to follow-up. Among 
children 6 months to less than 5 years of age, 497 (18.2%) in the annual treatment arm and 567 
(22.1%) in the biannual treatment arm moved out of the study area or were lost to follow-up 
during the study period. No significant differences were identified when comparing loss to 
follow-up by arm in this age group.  
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Antibiotic treatment coverage of children 6 months to less than 5 years of age is shown in Table 
2. All communities received 3 mass azithromycin distributions (June/July 2010, June/July 2011, 
and June/July 2012). The 24 biannual communities were treated an additional 3 times (December 
2010/January 2011, December 2011/January 2012, and December 2012/January 2013). The 
average treatment coverage of children 6 months to less than 5 years of age was greater than 
80% across all treatment periods in both arms. No serious adverse events were reported. 
Among children 6 months to less than 5 years of age, 231 deaths occurred in the annual arm and 
173 deaths occurred in the biannual arm during the 3-year study period. The mortality rate was 
35.3 deaths per 1000 person-years (95% CI 30.9 to 40.2) among children in the annual treatment 
arm and 28.9 deaths per 1000 person-years (95% CI 24.8 to 33.6) among children in the biannual 
treatment arm (Table 3). The mortality rate ratio comparing children 6 months to less than 5 
years old in the biannual arm to the annual arm was 0.81 (95% CI 0.66 to 1.00, P = 0.07, Table 
3). 
Exploratory analyses revealed similar results for the other age groups (Table 3). When children 
were combined into 1 age group, the mortality rate ratio comparing children 6 months to less 
than 12 years of age who received biannual azithromycin to those who received annual 
azithromycin was 0.82 (95% CI 0.67 to 0.99, P = 0.057) 
Verbal autopsy results are shown in Table 4. Of the 404 children 6 months to less than 5 years of 
age who died during the study period, verbal autopsy was available for 362 (89.6%). The most 
common causes of death in both arms were malaria (45.3%) and diarrhea (24.9%). The 
distribution of cause of death did not differ between the 2 arms (P = 0.36). The infectious disease 
mortality rate ratio comparing children who died from infectious causes in the biannual arm to 
the annual arm was 0.73 (95% CI 0.57 to 0.94, P=0.02). 
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DISCUSSION 
In this cluster-randomized trial, we found a non-significant 19% decrease in mortality rate in 
children 6 months to less than 5 years of age in biannually treated communities compared to 
annually treated communities (pre-specified analysis). Similar results were noted across the other 
age groups analyzed. No differences were identified in the distribution of attributed cause of 
death by arm, but there is a suggestion of a lower rate of mortality from infectious causes of 
death in the biannual arm. 
Previous trachoma studies have found significant reductions in childhood mortality among those 
receiving mass oral azithromycin compared to no treatment.(12, 13) A cohort study from 
Ethiopia suggested a direct protective effect of azithromycin after finding a decreased risk of all-
cause mortality in children under 5 who received azithromycin compared to household members 
who did not.(12) A cluster-randomized trial for trachoma in Ethiopia demonstrated a 50% 
reduction in mortality after mass azithromycin distributions compared to delayed treatment.(13) 
These prior studies each compared treated subjects to untreated subjects whereas the present 
study compared communities receiving different treatment frequencies. The trial in Ethiopia did 
compare varying frequencies of mass azithromycin distribution for trachoma, but these were 
combined into 1 treated group for the mortality analysis based on power calculations.(13) No 
prior study has compared mortality among groups receiving different azithromycin regimens. 
The mortality effects found in this study were similar in all age groups of the biannually treated 
communities, even among the untreated age groups. Children younger than 6 months received 
topical tetracycline in both arms, and adults 15 years and older were not treated in the biannual 
arm. It is possible that these results are due to indirect effects of biannual treatment on untreated 
individuals in the community. Oral azithromycin has been associated with indirect effects on 
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trachoma in previous studies, thus it is plausible this phenomenon extends to other childhood 
illnesses as well.(21) Alternatively, the randomization procedure could have resulted in the 
biannual treatment arm including communities that, on average, experienced less mortality than 
communities in the annual treatment arm did. Data were not collected on baseline infectious 
disease burden or mortality rates, though a comparison of available baseline characteristics did 
not indicate an imbalance across arms. Systematic bias may also explain reduced mortality seen 
in the untreated age groups of the biannually-treated communities. These communities received 
twice as many treatment visits, which may have led to increased interaction with the health care 
system. However, all study communities received biannual trachoma monitoring visits, which 
should have limited any Hawthorne-like effect. Finally, it is also possible that these results are 
simply due to chance as no significant effects of biannual azithromycin on mortality were 
identified in the primary analysis. 
This study is limited by the lack of an untreated or placebo-controlled arm for comparison of 
baseline mortality rates. There are also limitations inherent in conducting verbal autopsy as well 
as delayed and incomplete verbal autopsy data, which make it difficult to fully assess cause of 
death in this population. In addition, Niger has among the highest childhood mortality rates in 
the world, thus results from this setting may not be generalizable to others.(22) Finally, this study 
was not powered to assess mortality as a primary outcome. If there were in fact a 20% effect of 
biannual azithromycin on mortality compared to annual azithromycin, a larger study would be 
required to have a reasonable chance of detecting it. A large, multi-site, cluster-randomized trial 
is currently underway to directly assess both the effects of biannual azithromycin on mortality 
among children under 5 as well as the effect of such an intervention on macrolide resistance 
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(MORDOR, Bill & Melinda Gates Foundation grant # OPP1032340-B, clinicaltrials.gov 
NCT02047981).  
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FIGURE 1 LEGEND 
1
CONSORT, Consolidated Standards of Reporting Trials. 
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Table 1. Baseline characteristics of children 6 months to less than 5 years of age in 48 
communities randomized to annual or biannual mass azithromycin in a cluster-randomized trial 
in Niger 
 Mean (95% CI) 
Characteristic 
Annual 
24 communities 
Biannual 
24 communities 
Participants per community  114 (88-156) 107 (89-127) 
Age (years) 2.4 (2.3-2.4) 2.4 (2.4-2.4) 
Proportion female, % 51.8% (50.2%-53.3%) 48.9% (46.7%-51.1%) 
Prevalence trachoma TF* 29.5% (23.5%-36.4%) 26.7% (21.9%-32.8%) 
Prevalence trachoma TI*  9.1% (6.3%-12.6%) 8.4% (6.0%-11.2%) 
*TF, trachomatous inflammation – follicular; TI, trachomatous inflammation – intense per the WHO 
Simplified Grading System. 
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Table 2. Average antibiotic treatment coverage of children 6 months to less than 5 years of age 
in 48 communities in Niger over 3 years 
 
 Mean (95% CI) 
Time point  
(months after study initiation) 
Annual 
24 communities 
Biannual 
24 communities 
0  
92.3% 
 (90.3%-94.1%) 
88.4% 
 (84.8%-91.8%) 
6   
85.3% 
 (81.8%-88.6%) 
12  
89.2% 
 (86.9%-91.3%) 
87.7% 
 (84.7%-90.6%) 
18   
87.3%  
(83.3%-90.5%) 
24  
90.1%  
(88.1%-91.9%) 
87.2%  
(84.4%-89.4%) 
30   
84.1%  
(80.6%-87.4%) 
36  
84.7% 
 (81.2%-88.1%) 
84.6%  
(81.0%-88.2%) 
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Table 3. Comparison of community-level mortality rates by treatment arm and age group 
 
Age group
1 
Mortality rates per 1000 person-years (95% CI) 
[number of deaths]
 
Rate ratio 
(95% CI)
4 P-value
4 
Annual
2 
24 communities 
Biannual
3 
24 communities 
<6 months old 83.0 (62.8-109.6) [71] 76.3 (57.8-100.9) [66] 
0.92 (0.62-
1.37) 
0.61 
6 months to <5 
years old 
35.6 (30.9-40.9) [231] 29.0 (24.8-33.8) [173] 
0.81 (0.66-
1.00) 
0.07 
5 years to <12 
years old 
6.8 (5.2-8.8) [71] 5.6 (4.1-7.4) [53] 
0.82 (0.56-
1.22) 
0.20 
≥15 
years 
old 
9.8 (8.4-11.5) [155] 8.4 (7.1-10.0) [132] 
0.86 (0.68-
1.08) 
0.20 
1
Mortality in participants 6 months to less than 5 years of age was a pre-specified outcome of the trial.  
2
In the annually-treated communities, study participants 6 months and older received oral azithromycin. Children 
younger than 6 months old were offered tetracycline ointment instead of oral azithromycin.  
3
In the biannually-treated communities, study participants 6 months to 12 years of age received oral azithromycin. 
Children younger than 6 months old were offered tetracycline ointment instead of oral azithromycin.  
4
Rate ratios and confidence intervals estimated by negative binomial regression; P-values estimated by Monte Carlo 
permutation (n=16,384) at the level of the randomization unit (community), accounting for the stratified design. 
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Table 4. Causes of death among children 6 months to less than 5 years of age in the annual 
and biannual treatment arms as ascertained by verbal autopsy.1 
 
1
P-value = 0.36 (chi-squared test for comparison of primary cause of death by arm with permuted P-value). 
2
Causes of death ordered according to expert hierarchical algorithm. 
 
 
 
 
  
Primary cause of death
2 
Annual 
24 communities 
Biannual 
24 communities 
Total 
48 communities 
Total % Total % Total % 
Injury 1 0.5% 3 2.0% 4 1.1% 
AIDS 5 2.4% 5 3.4% 10 2.8% 
Measles 3 1.4% 1 0.67% 4 1.1% 
Meningitis 4 1.9% 0 0.0% 4 1.1% 
Dysentery 12 5.6% 6 4.0% 18 5.0% 
Diarrhea 61 28.6% 29 19.5% 90 24.9% 
Pertussis 1 0.5% 2 1.3% 3 0.8% 
Pneumonia 8 3.8% 6 4.0% 14 3.9% 
Malaria 89 41.8% 75 50.3% 164 45.3% 
Hemorrhagic fever 0 0.0% 1 0.7% 1 0.3% 
Other infection 12 5.6% 7 4.7% 19 5.2% 
Malnutrition 7 3.3% 7 4.7% 14 3.9% 
Unspecified 10 4.7% 7 4.7% 17 4.7% 
Total
 
213 100.0% 149 100.0% 362 100.0% 
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